Otsuka Pharmaceutical Co., Ltd. ' Product Pipeline Review ' 2012

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Otsuka Pharmaceutical Co., Ltd. ' Product Pipeline Review ' 2012
Published on December 2012

Report Summary


Summary

Global Market Direct's pharmaceuticals report, "Otsuka Pharmaceutical Co., Ltd. - Product Pipeline Review - 2012" provides data on
the Otsuka Pharmaceutical Co., Ltd.'s research and development focus. The report includes information on current developmental
pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Otsuka Pharmaceutical
Co., Ltd.'s corporate website, SEC filings, investor presentations and featured press releases, both from Otsuka Pharmaceutical Co.,
Ltd. and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- Otsuka Pharmaceutical Co., Ltd. - Brief Otsuka Pharmaceutical Co., Ltd. overview including business description, key information
and facts, and its locations and subsidiaries.
- Review of current pipeline of Otsuka Pharmaceutical Co., Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities,
across the globe.
- Product profiles for late stage and clinical stage products of Otsuka Pharmaceutical Co., Ltd. with complete description of the
product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Otsuka Pharmaceutical Co., Ltd.'s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Otsuka Pharmaceutical Co., Ltd.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Otsuka Pharmaceutical Co., Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Otsuka Pharmaceutical Co., Ltd.'s R&D portfolio and develop key strategic
initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Otsuka Pharmaceutical Co., Ltd..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Otsuka Pharmaceutical Co., Ltd. and identify potential opportunities in those
areas.

Otsuka Pharmaceutical Co., Ltd. ' Product Pipeline Review ' 2012 (From Slideshare) Page 1/8


Table of Content

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Otsuka Pharmaceutical Co., Ltd. Snapshot 7
Otsuka Pharmaceutical Co., Ltd. Overview 7
Key Information 7
Key Facts 7
Otsuka Pharmaceutical Co., Ltd. ' Research and Development Overview 8
Key Therapeutic Areas 8
Otsuka Pharmaceutical Co., Ltd. ' Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products ' Monotherapy 12
Otsuka Pharmaceutical Co., Ltd. ' Pipeline Products Glance 13
Otsuka Pharmaceutical Co., Ltd. ' Late Stage Pipeline 13
Registration Filed Products/Combination Treatment Modalities 13
Phase III Products/Combination Treatment Modalities 14
Otsuka Pharmaceutical Co., Ltd. Clinical Stage Pipeline Products 15
Phase II Products/Combination Treatment Modalities 15
Phase I Products/Combination Treatment Modalities 16
Otsuka Pharmaceutical Co., Ltd. ' Early Stage Pipeline Products 17
Pre-Clinical Products/Combination Treatment Modalities 17
Otsuka Pharmaceutical Co., Ltd. ' Drug Profiles 18
aripiprazole 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
OCV-501 21
R&D Progress 21
OPB-111001 22
R&D Progress 22
OPC-108459 23
R&D Progress 23
Progranulin 24
R&D Progress 24



Sativex 25
R&D Progress 25
Otsuka Pharmaceutical Co., Ltd. ' Pipeline Products by Route of Administration 28
Otsuka Pharmaceutical Co., Ltd. ' Pipeline Products By Mechanism of Action 29
Otsuka Pharmaceutical Co., Ltd. ' Recent Pipeline Updates 30
Otsuka Pharmaceutical Co., Ltd. - Dormant Projects 35
Otsuka Pharmaceutical Co., Ltd. ' Locations And Subsidiaries 36
Head Office 36
Otsuka Pharmaceutical Co., Ltd., Recent Developments 37
Otsuka Pharmaceutical Co., Ltd.- Press Release 37
Dec 21, 2012: Otsuka Pharma And Lundbeck Initiate Regulatory Process For Aripiprazole Depot Formulation In Europe 37
Dec 13, 2012: Otsuka Pharma's Abilify Receives CHMP Positive Opinion For Treatment Of Moderate To Severe Manic Episodes In
Bipolar I Disorder 38
Sep 12, 2012: Lundbeck And Otsuka Announce FDA Acceptance For Resubmission Of New Drug Application For Aripiprazole Depot
Formulation 38
Sep 03, 2012: Otsuka Pharma Files Additional Indication Application For Abilify For Treatment Of Depression 39
Jul 27, 2012: Otsuka Receives Complete Response Letter For Extended-Release Injectable Suspension Of Aripiprazole 39
Jul 24, 2012: Catalent Commences Supply Of Abilify Orally Disintegrating Tablets To Otsuka Pharma 39
May 08, 2012: Otsuka Announces Federal Court Decision Affirming Validity Of ABILIFY Patent 40
May 07, 2012: Lundbeck And Otsuka Pharma Presents Phase III Study Results Of Aripiprazole Intramuscular Depot Formulation For
Treatment Of Schizophrenia 40
May 07, 2012: Otsuka And Lundbeck Announce Results From Phase III Clinical Trial Of Aripiprazole Intramuscular Depot Formulation
For Schizophrenia 42
Jan 18, 2012: Otsuka Pharmaceutical Receives Regulatory Approvals For Additional Indication For ABILIFY And For New Dosage
Form ABILIFY OD Tablets 44
Apr 06, 2009: Bristol-Myers Squibb Announces Extension of U.S. Agreement for ABILIFY and Establishment of an Oncology
Collaboration with Otsuka 45
Feb 04, 2009: US FDA Lists Bristol-Myers Squibb Company , Roche Holding AG , Eli Lilly And Company , Pfizer Inc. And
GlaxoSmithKline's Drugs Under Review For Safety Issues 46
Financial Deals Landscape 47
Otsuka Pharmaceutical Co., Ltd., Deals Summary 47
Otsuka Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deal Details 51
Asset Transactions 51
Otsuka Pharma Acquires Rights To IV Busulfex From PDL Biopharma 51
Venture Financing 53
GangaGen Secures $5.4 Million In Series E Financing 53
SomaLogic Secures $35 Million In Series A Financing 55
Partnerships 57
Otsuka Pharma Forms Joint Venture With Abdi Ibrahim To Market Otsuka's Drugs In Turkey 57
Otsuka Pharma Amends Co-Development Agreement With UCB 59
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma 68
Acucela Enters Into Co-Development Agreement With Otsuka Pharma For OPA-6566 70
MethylGene Extends Its Research Collaboration With Otsuka Pharma 72
GW Pharma Expands Its Cannabinoid Research Collaboration With Otsuka 74
Penwest Enters Into Research And Development Agreement With Otsuka Pharma 76
Penwest Enters Into Co-Development Agreement With Otsuka Pharma 77



Bristol-Myers Squibb Extends Co-Development Agreement With Otsuka 78
Bristol Enters Into Co-Marketing Agreement With Otsuka 80
Otsuka Pharma Enters Into Agreement With Bristol-Myers 82
Dong-A Enters Into Agreement With Otsuka Pharma 88
Acucela Enters Into Co-Development Agreement With Otsuka Pharma For Rebamipide 90
Acucela Enters Into Co-Development Agreement With Otsuka Pharma For ACU-4429 92
Otsuka Pharma Enters Into A Co-Development Agreement With UCB 94
UCB Enters Into Co-Promotion Agreement With Otsuka Pharma For Keppra And Cimzia 96
UCB Enters Into Co-Promotion Agreement With Otsuka For Pletaal 105
SomaLogic Enters Into Research Collaboration With Otsuka Pharma 106
Penwest Pharma Enters Into Research Agreement With Otsuka Pharma 107
Chugai Pharma Enters Into Co-Promotion Agreement With Otsuka Pharma 108
Licensing Agreements 109
Fuso Pharma Enters Into Licensing Agreement With Otsuka Pharma 109
BioWa Enters Into Licensing Agreement With Otsuka Pharma 110
Proteus Biomedical Enters Into Licensing Agreement With Otsuka Pharma 111
Otsuka Pharma Enters Into Licensing Agreement With Kyowa Hakko Kirin For Saxagliptin 112
Galenea Extends Licensing Agreement With Otsuka Pharma 114
Otsuka Pharma Extends Its Licensing Agreement With MethylGene 115
ISTA Pharma Amends License And Supply Agreement With Otsuka Pharma 116
Methylgene Enters Into Collaboration And Licensing Agreement With Otsuka 119
OncoTherapy Science Enters Into Agreement With Otsuka Pharma 120
GW Pharma Enters Into Licensing Agreement With Otsuka Pharma 121
Bristol-Myers Squibb Signs A Licensing Agreement With Otsuka Pharma 122
Acquisition 123
Otsuka Pharma Acquires Nutrition & Sante From Abenex Capital And L Capital 123
Otsuka Pharma Acquires Interpharma Praha 125
Otsuka Pharma Acquires Minority Interest In Eiken Chemical 126
Appendix 127
Methodology 127
Coverage 127
Secondary Research 127
Primary Research 127
Expert Panel Validation 127
Contact Us 128
Disclaimer 128

List of Tables

Otsuka Pharmaceutical Co., Ltd., Key Information 7
Otsuka Pharmaceutical Co., Ltd., Key Facts 7
Otsuka Pharmaceutical Co., Ltd. ' Pipeline by Indication, 2012 9
Otsuka Pharmaceutical Co., Ltd. ' Pipeline by Stage of Development, 2012 11
Otsuka Pharmaceutical Co., Ltd. ' Monotherapy Products in Pipeline, 2012 12



Otsuka Pharmaceutical Co., Ltd. ' Filed, 2012 13
Otsuka Pharmaceutical Co., Ltd. ' Phase III, 2012 14
Otsuka Pharmaceutical Co., Ltd. ' Phase II, 2012 15
Otsuka Pharmaceutical Co., Ltd. ' Phase I, 2012 16
Otsuka Pharmaceutical Co., Ltd. ' Pre-Clinical, 2012 17
Otsuka Pharmaceutical Co., Ltd. ' Pipeline By Route of Administration, 2012 28
Otsuka Pharmaceutical Co., Ltd. ' Pipeline Products By Mechanism of Action, 2012 29
Otsuka Pharmaceutical Co., Ltd. ' Recent Pipeline Updates, 2012 30
Otsuka Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2012 35
Otsuka Pharmaceutical Co., Ltd., Deals Summary 47
Otsuka Pharma Acquires Rights To IV Busulfex From PDL Biopharma 51
GangaGen Secures $5.4 Million In Series E Financing 53
SomaLogic Secures $35 Million In Series A Financing 55
Otsuka Pharma Forms Joint Venture With Abdi Ibrahim To Market Otsuka's Drugs In Turkey 57
Otsuka Pharma Amends Co-Development Agreement With UCB 59
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma 68
Acucela Enters Into Co-Development Agreement With Otsuka Pharma For OPA-6566 70
MethylGene Extends Its Research Collaboration With Otsuka Pharma 72
GW Pharma Expands Its Cannabinoid Research Collaboration With Otsuka 74
Penwest Enters Into Research And Development Agreement With Otsuka Pharma 76
Bristol-Myers Squibb Extends Co-Development Agreement With Otsuka 78
Bristol Enters Into Co-Marketing Agreement With Otsuka 80
Otsuka Pharma Enters Into Agreement With Bristol-Myers 82
Dong-A Enters Into Agreement With Otsuka Pharma 88
Acucela Enters Into Co-Development Agreement With Otsuka Pharma For Rebamipide 90
Acucela Enters Into Co-Development Agreement With Otsuka Pharma For ACU-4429 92
Otsuka Pharma Enters Into A Co-Development Agreement With UCB 94
UCB Enters Into Co-Promotion Agreement With Otsuka Pharma For Keppra And Cimzia 96
UCB Enters Into Co-Promotion Agreement With Otsuka For Pletaal 105
SomaLogic Enters Into Research Collaboration With Otsuka Pharma 106
Penwest Pharma Enters Into Research Agreement With Otsuka Pharma 107
Chugai Pharma Enters Into Co-Promotion Agreement With Otsuka Pharma 108
Fuso Pharma Enters Into Licensing Agreement With Otsuka Pharma 109
BioWa Enters Into Licensing Agreement With Otsuka Pharma 110
Proteus Biomedical Enters Into Licensing Agreement With Otsuka Pharma 111
Otsuka Pharma Enters Into Licensing Agreement With Kyowa Hakko Kirin For Saxagliptin 112
Otsuka Pharma Extends Its Licensing Agreement With MethylGene 115
ISTA Pharma Amends License And Supply Agreement With Otsuka Pharma 116
Methylgene Enters Into Collaboration And Licensing Agreement With Otsuka 119
OncoTherapy Science Enters Into Agreement With Otsuka Pharma 120
GW Pharma Enters Into Licensing Agreement With Otsuka Pharma 121
Bristol-Myers Squibb Signs A Licensing Agreement With Otsuka Pharma 122
Otsuka Pharma Acquires Nutrition & Sante From Abenex Capital And L Capital 123
Otsuka Pharma Acquires Interpharma Praha 125



Otsuka Pharma Acquires Minority Interest In Eiken Chemical 126

List of Figures

Otsuka Pharmaceutical Co., Ltd. ' Pipeline by Indication, 2012 9
Otsuka Pharmaceutical Co., Ltd. ' Pipeline by Stage of Development, 2012 11
Otsuka Pharmaceutical Co., Ltd. ' Monotherapy Products in Pipeline, 2012 12
Otsuka Pharmaceutical Co., Ltd. ' Pipeline By Route of Administration, 2012 28
Otsuka Pharmaceutical Co., Ltd. - Pipeline Products By Mechanism of Action, 2012 29


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.


Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 1 500.00 Quantity: _____

Site License--USD 3 000.00 Quantity: _____

Corporate License--USD 4 500.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Otsuka Pharmaceutical Co., Ltd. ' Product Pipeline Review ' 2012

Recomendados

Recomendados

Más contenido relacionado

Destacado

Destacado (10)

Más de ReportLinker.com

Más de ReportLinker.com (20)

Otsuka Pharmaceutical Co., Ltd. ' Product Pipeline Review ' 2012